• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    US Stocks Edge Higher On Last Trading Day Of 2023; Chicago PMI Falls In December

    12/29/23 9:58:46 AM ET
    $ADTX
    $CGA
    $CING
    $GMM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Agricultural Chemicals
    Industrials
    Get the next $ADTX alert in real time by email

    U.S. stocks traded slightly higher this morning, with the Dow Jones index gaining around 10 points on Friday.

    Following the market opening Friday, the Dow traded up 0.03% to 37,723.19 while the NASDAQ rose 0.02% to 15,098.01. The S&P 500 also rose, gaining, 0.05% to 4,785.65.

    Check This Out: How To Earn $500 A Month From Annaly Capital Management Stock

     

    Leading and Lagging Sectors

     

    Utilities shares jumped by 0.6 on Friday.

    In trading on Friday, energy shares fell by 0.9%.

     

    Top Headline

     

    The Chicago PMI fell to 46.9 in December from 55.8 in the previous month, and compared to market estimates of 51.

     

    Equities Trading UP

     

    China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) shares shot up 158% to $5.34.

    Shares of China Green Agriculture, Inc. (NYSE:CGA) got a boost, surging 70% to $3.23. On Dec. 27, China Green Agriculture entered into a stock purchase agreement with Zhibiao Pan for the acquisition of all outstanding stock of Lonestar Dream for a total consideration of $49 million.

    Aditxt, Inc. (NASDAQ:ADTX) shares were also up, gaining 58% to $7.62. Aditxt recently entered into definitive agreement to acquire Evofem Biosciences, Inc.

     

    Equities Trading DOWN

     

    Global Mofy Metaverse Limited (NASDAQ:GMM) shares dropped 36% to $7.10.
    Global Mofy Metaverse announced a $10 million follow-on offering.

    Shares of Ucommune International Ltd (NASDAQ:UK) were down 26% to $3.8446 after jumping over 71% on Thursday. Ucommune recently regained compliance with Nasdaq minimum bid price requirement.

    Cingulate Inc. (NASDAQ:CING) was down, falling 21% to $7.73. Cingulate shares jumped 146% on Thursday after the company announced it received guidance from the FDA regarding its clinical program for CTx-1301.

    Also Check This Out: Top 4 Tech And Telecom Stocks That May Fall Off A Cliff In Q4

     

    Commodities

     

    In commodity news, oil traded up 1% to $72.47 while gold traded down 0.7% at $2,069.30.

    Silver traded down 2.1% to $23.85 on Friday while copper fell 0.8% to $3.8945.

     

    Euro zone

     

    European shares were higher today. The eurozone’s STOXX 600 gained 0.2%, London’s FTSE 100 rose 0.1% while Spain’s IBEX 35 Index rose 0.5% The German DAX rose 0.3% French CAC 40 rose 0.3% while Italy’s FTSE MIB Index rose 0.4%.

    Spain posted a current account surplus of EUR 3,770 million in October versus a year-ago surplus of EUR 1,228 million. Spain's consumer price inflation eased to 3.1% year-over-year in December from 3.2% in the prior month. The Nationwide House Price Index in the U.K. fell by 1.8% year-over-year in December.

     

    Asia Pacific Markets

     

    Asian markets closed mixed on Friday, with Japan’s Nikkei 225 falling 0.22%, Hong Kong’s Hang Seng Index rising 0.02% and China’s Shanghai Composite Index gaining 0.68%. India’s S&P BSE Sensex, meanwhile, fell 0.23%.

    China reported a current account surplus of $62.8 billion in the third quarter, compared to the preliminary estimate of $62.6 billion.

     

    Economics

     

    The Chicago PMI fell to 46.9 in December from 55.8 in the previous month, and compared to market estimates of 51.

    Crude oil inventories in the U.S. declined by 6.911 million barrels in the week ending Dec. 22, falling the most in four months and compared to market estimates of a 2.704 million-barrel decline.

    Now Read This: Accenture, Lyft And 2 Other Stocks Insiders Are Selling

     

    Get the next $ADTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTX
    $CGA
    $CING
    $GMM

    CompanyDatePrice TargetRatingAnalyst
    Cingulate Inc.
    $CING
    1/10/2025$12.00Buy
    ROTH MKM
    Cingulate Inc.
    $CING
    12/22/2023Buy → Hold
    Laidlaw
    Cingulate Inc.
    $CING
    1/20/2022$8.50Buy
    Laidlaw & Co.
    Cingulate Inc.
    $CING
    1/11/2022$9.00Buy
    Aegis Capital
    More analyst ratings

    $ADTX
    $CGA
    $CING
    $GMM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    China SXT Pharmaceuticals, Inc. Announces Share Re-classification

    TAIZHOU, China, March 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (NASDAQ:SXTC) (the "Company" or "SXTC"),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that upon the market opening on March 24, 2026, the Company's Class A Ordinary Shares will be traded on The Nasdaq Stock Market under the symbol "SXTC". On July 28, 2025, the Company held a special meeting of shareholders (the "Meeting"). At the Meeting

    3/23/26 9:00:00 AM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

    Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most

    3/19/26 8:15:00 AM ET
    $ADTX
    $GMRE
    $XRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    KANSAS CITY, Kan., March 18, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended December 31, 2025, and provided a corporate update. Highlights include recent U.S. and European patent developments, the closing of a $12 million private investment, and the acceptance of a New Drug Application (NDA) for its lead candidate, CTx-1301 (dexmethylphenidate HCl). Cingulate CEO Shane J. Schaffer stated, "Cingulate delivered on key inflection points throughout 2025 and this continues i

    3/18/26 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $CGA
    $CING
    $GMM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. bought $34,317 worth of shares (6,809 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:19 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Werth Peter J. bought $98,053 worth of shares (19,455 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $CGA
    $CING
    $GMM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and CSO Silva Raul R. was granted 4,526 shares and covered exercise/tax liability with 1,828 shares, increasing direct ownership by 139% to 4,645 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    3/11/26 8:13:31 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CLO and CCO Patel Nilay Dahyabhai was granted 5,475 shares and covered exercise/tax liability with 2,086 shares (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    3/11/26 8:13:27 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. was granted 6,862 shares and covered exercise/tax liability with 2,959 shares, increasing direct ownership by 2,256% to 4,076 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    3/11/26 8:13:30 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $CGA
    $CING
    $GMM
    SEC Filings

    View All

    SEC Form DEF 14A filed by Aditxt Inc.

    DEF 14A - Aditxt, Inc. (0001726711) (Filer)

    4/3/26 4:37:32 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. filed SEC Form 8-K: Leadership Update

    8-K - Cingulate Inc. (0001862150) (Filer)

    4/2/26 4:05:28 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt Inc. filed SEC Form 8-K: Other Events

    8-K - Aditxt, Inc. (0001726711) (Filer)

    4/2/26 9:13:36 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $CGA
    $CING
    $GMM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Cingulate with a new price target

    ROTH MKM initiated coverage of Cingulate with a rating of Buy and set a new price target of $12.00

    1/10/25 7:39:52 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate downgraded by Laidlaw

    Laidlaw downgraded Cingulate from Buy to Hold

    12/22/23 7:22:08 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Laidlaw & Co. initiated coverage on Cingulate with a new price target

    Laidlaw & Co. initiated coverage of Cingulate with a rating of Buy and set a new price target of $8.50

    1/20/22 9:15:46 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $CGA
    $CING
    $GMM
    Leadership Updates

    Live Leadership Updates

    View All

    Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

    Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most

    3/19/26 8:15:00 AM ET
    $ADTX
    $GMRE
    $XRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ended September 30, 2025, and provided recent corporate highlights. Recent Highlights (Post-Q3) FDA Accepts NDA for CTx-1301; PDUFA Date Set for May 31, 2026In October of 2025, the U.S. Food and Drug Administration (FDA) accepted Cingulate's New Drug Application

    11/13/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

    Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate's transition toward commercialization pending FDA approval Company also strengthens its cash position by completing a $6 million financing KANSAS CITY, Kan., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced the appointment of Bryan Downey as Chief Commercial Officer, following the U.S. Food and Drug Administration's (FDA) acceptance of Cingulate's New Drug Application (ND

    11/10/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $CGA
    $CING
    $GMM
    Financials

    Live finance-specific insights

    View All

    Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

    Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC ("Ignite"), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone. Aditxt

    3/13/26 8:15:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

    Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended June 30, 2025, and provided recent highlights. Recent Highlights: On July 31, 2025, Cingulate submitted its NDA to the FDA for CTx-1301, a novel, extended-release tablet formulation

    8/19/25 8:45:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

    -- Increased Net Sales and Improved Loss from Operations in Q2 2025 vs. Prior Year Quarter -- -- Evofem Advances Plans for Special Meeting of Stockholders to Approve the A&R Merger Agreement and Become a Wholly-owned Subsidiary of Aditxt --  SAN DIEGO, Aug. 14, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and six-month periods ended June 30, 2025 and provided a business update. Notable developments since April 1st include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Bioscienc

    8/14/25 8:46:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $CGA
    $CING
    $GMM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc.

    SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

    10/25/24 12:19:29 PM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ucommune International Ltd

    SC 13G/A - Ucommune International Ltd (0001821424) (Subject)

    10/16/24 6:05:14 AM ET
    $UK
    Real Estate